title: Serum testosterone, androstenedione and luteinizing hormone levels after short-term medroxyprogesterone acetate treatment in women with polycystic ovarian disease.
abstract: BACKGROUND
  Medroxyprogesterone acetate (MPA)-treatment suppresses serum gonadotropin and androgen concentrations in women with polycystic ovarian disease (PCOD). This study was designed to determine serum testosterone (T), androstenedione (A) and luteinizing hormone (LH) patterns in a group of oligomenorrheic PCOD patients after MPA-treatment.
  
  
  METHODS
  The study group consisted of 11 women with ultrasonographically diagnosed PCOD. Blood samples were drawn in the morning in fasting conditions first during oligomenorrhea and then within one week after MPA-induced bleeding. After that the sampling was repeated four times at one week intervals. Student's paired t-test was used for statistical calculations.
  
  
  RESULTS
  The levels of T, A and LH decreased significantly after MPA-treatment. During the follow-up the T and A concentrations increased significantly till the third sampling week, after which no further increases were found.
  
  
  CONCLUSIONS
  Our results show that T and A secretion return to levels characteristic of PCOD after discontinuation of MPA-treatment within a few weeks in women with PCOD.
authors.affiliation: Department of Obstetrics and Gynecology, Turku University Central Hospital, Finland.
authors.forename: L
authors.initials: L
authors.lastname: Anttila
authors.forename: P
authors.initials: P
authors.lastname: Koskinen
authors.forename: R
authors.initials: R
authors.lastname: Erkkola
authors.forename: K
authors.initials: K
authors.lastname: Irjala
authors.forename: K
authors.initials: K
authors.lastname: Ruutiainen
mesh_terms: D000328:Adult; D000735:Androstenedione / Q000037:antagonists & inhibitors / Q000097:blood*; D005260:Female; D005387:Finland; D006801:Humans; D007986:Luteinizing Hormone / Q000037:antagonists & inhibitors / Q000097:blood*; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D009839:Oligomenorrhea / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy; D013739:Testosterone / Q000037:antagonists & inhibitors / Q000097:blood*; D014463:Ultrasonography
chemical_list: D013739:Testosterone; D000735:Androstenedione; D007986:Luteinizing Hormone; D017258:Medroxyprogesterone Acetate